Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA7 | P43166 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402038 | 0.89 | KDM4E (0.55) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL282481 | 0.85 | KDM4E (0.63) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL28510333 | 0.84 | KDM4E (0.46) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL29634023 | 0.84 | KDM4E (0.46) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL21455367 | 0.84 | KDM4E (0.46) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL13449170 | 0.83 | TTR (0.48) | KDM4ELMNAPOLBESR1TTR | |
| SCHEMBL8640946 | 0.81 | TPMT (0.50) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL1638962 | 0.80 | TTR (0.67) | KDM4ELMNAFUT7TDP1CA12 | |
| SCHEMBL8539124 | 0.80 | XDH (0.74) | KDM4EXDHLMNAPOLBGAA | |
| SCHEMBL12666450 | 0.79 | KDM4E (0.52) | KDM4EXDHLMNAPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| EP-4524133-A2 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3939658-B1 | SUBSTITUTED BENZOPYRROLE AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | BIOCRYST PHARM INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-09-05 | — | — | US | disclosed |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117615763-A | Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof | 健道生物医药有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-11866418-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4284375-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117164499-A | Substituted benzofurans, benzopyrroles, benzothiophenes and structurally related complement inhibitors | 拜奥克里斯特制药公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2012140419-A1 | CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | WO | disclosed |
| EP-2493870-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051704-A1 | CHROMENONE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098271-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| EP-0628543-B1 | Substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them | HOECHST AG (DE) | 1999-06-16 | — | — | EP | disclosed |
| US-5849775-A | Substituted benzoylguanidines process for their preparation, their use as a medicament or diagnostic, and pharmaceutical containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| US-5679712-A | ANTIARRHYTHMIA AGENTS, TREATMENT OF CARDIOVASCULAR, NERVOUS SYSTEM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098271-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND3 | KDM4E 2576/4885XDH 792/4885LMNA 512/4885 |
| US-20240294494-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | C9, C5, C1QBP | KDM4E 2522/4885XDH 63/4885LMNA 2763/4885 |
| US-12043610-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | KDM4E 2522/4885XDH 63/4885LMNA 2763/4885 |
| US-11866418-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | KDM4E 2522/4885XDH 63/4885LMNA 2763/4885 |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | KDM4E 1536/4885XDH 183/4885LMNA 3855/4885 |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CB, PI4KA | KDM4E 1629/4885XDH 4182/4885LMNA 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.